Abstract: An in vitro method of classifying a subject suspected to suffer from an acute event including the steps of: determining neopterin concentration in a biological sample obtained from the subject, comparing the concentration with a predetermined reference neopterin concentration, and assigning the subject to a risk group based on the comparison of the neopterin concentration with the predetermined reference neopterin concentration.
Type:
Application
Filed:
July 12, 2021
Publication date:
August 10, 2023
Applicants:
SORBONNE UNIVERSITÉ, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
Abstract: Disclosed is a method utilizing (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or an analogue, pharmaceutically acceptable salt or solvate thereof for the treatment of a retinal disease, more specifically using mirabegron for the treatment of age-related macular degeneration. Also Disclosed is a pharmaceutical composition, a medicament and a kit for the treatment of age-related macular degeneration.
Type:
Grant
Filed:
November 17, 2016
Date of Patent:
August 8, 2023
Assignees:
SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
Abstract: The invention is in the field of therapy of antibody deficiencies. Inventors demonstrate for the first time in both controls and IgA-deficient patients, systemic anti-microbiota IgG responses correlate with reduced inflammation suggesting that systemic IgG responses contribute to the gut microbiota confinement. Furthermore, SIgAd-associated inflammation is inversely correlated with systemic anti-commensal IgG responses, which may thus serve as a second line of defense. Altogether, these data suggest that systemic IgG and intestinal IgA cooperate in different body compartments to limit systemic pro-inflammatory pathways. As selective IgA deficient patients harbour elevated seric anti-commensal IgG levels, these findings suggest that in selective IgA deficiency, microbiota confinement is obtained at the price of a strong inflammatory response.
Type:
Grant
Filed:
October 29, 2019
Date of Patent:
August 8, 2023
Assignees:
INSERM (Instut National de la Santé et de la Recherche Médicale), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP)
Inventors:
Guy Gorochov, Martin Larsen, Delphine Sterlin, Jehane Fadlallah
Abstract: A process for pre-concentration and detection of at least one single-stranded nucleic acid target molecule, the process comprising the steps of generating a flow of liquid comprising at least one magnetic nanoparticle in a micro-channel and a plurality of single-stranded nucleic acid probe molecules attached to the nanoparticle, generating an alternating magnetic field in the part of the micro-channel using an electromagnet, the magnetic field having an intensity and frequency that are suitable for causing magnetic hyperthermia of the nanoparticles so as to cause denaturing of the duplex formed by the single-stranded nucleic acid target molecule and the single-stranded nucleic acid probe molecule, and detecting the single-stranded target molecule dispersed in the liquid.
Type:
Grant
Filed:
October 5, 2018
Date of Patent:
August 1, 2023
Assignees:
Centre National de la Recherche Scientifique (CNRS), Institut National de La Sante et de la Recherche Medicale (INSERM), Sorbonne Universite
Inventors:
Marie-Charlotte Horny, Jean-Michel Siaugue, Vincent Dupuis, Mathieu Lazerges, Jean Gamby
Abstract: The present invention concerns a compound of formula (I), or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.
Type:
Grant
Filed:
March 29, 2021
Date of Patent:
July 25, 2023
Assignees:
AGV Discovery, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite De Montpellier
Abstract: An expression vector containing appropriate mitochondrion-targeting sequences (MTS) and appropriate 3?UTR sequences provides efficient and stable delivery of a mRNA encoding a protein (CDS) to the mitochondrion of a mammalian cell. The MTS and 3?UTR sequences guide the CDS mRNA from the nuclear compartment of the cell to mitochondrion-bound polysomes, where the CDS is translated. This provides an efficient translocation of a mature functional protein into the mitochondria. A method of targeting mRNA expressed in the nuclear compartment of a mammalian cell to the mitochondrion is also provided. The vector and methods can be used to treat defects in mitochondrial function.
Type:
Grant
Filed:
May 26, 2021
Date of Patent:
July 18, 2023
Assignee:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
Type:
Grant
Filed:
March 13, 2020
Date of Patent:
July 18, 2023
Assignees:
INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paul Sabatier Toulouse III
Abstract: The invention relates to the use of an iron-score based on the expression level of at least 2 genes, in particular at least 5, preferably at least 10, and even preferably 11 genes selected in the group consisting of ALAS1, HIF1A, LRP2, HMOX1, HMOX2, HFE, ISCA1, SLC25A37, PPOX, STEAP1 and TMPRSS6 involved in the iron metabolism, as a prognosis marker in subjects having DLBCL, in particular for identifying subjects with a poor outcome such as a relapse and/or death.
Type:
Application
Filed:
November 6, 2020
Publication date:
July 13, 2023
Applicants:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE DE MONTPELLIER, INSTITUT CURIE
Abstract: Disclosed is a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside.
Type:
Grant
Filed:
December 5, 2017
Date of Patent:
July 11, 2023
Assignees:
OGD2 PHARMA, NANTES UNIVERSITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT DE CANCEROLOGIE DE L'OUEST
Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth regardation disorders, such as achondroplasia.
Type:
Grant
Filed:
April 20, 2021
Date of Patent:
July 11, 2023
Assignees:
Pfizer Inc., INSERM (Institut National de la Santé et de la Recherche Médicale), Université Côte d'Azur
Abstract: The invention relates to a method for increasing the lifespan of animal sperm comprising contacting said sperm with an inhibitor of Slo3 potassium channel. The invention also relates to a use of an inhibitor of Slo3 potassium channel, for increasing the lifespan of animal sperm or motility of capacitated animal sperm, comprising contacting an inhibitor of Slo3 potassium channel with said sperm. Moreover, the invention relates to an artificial insemination instrument for use in artificial insemination of an animal, comprising animal sperm in contact with an inhibitor of Slo3 potassium channel. The invention also relates to a method for artificially inseminating an animal using said artificial insemination instrument. Eventually, the invention relates to a method for increasing the fertility of an animal, comprising contacting sperm of said animal with an inhibitor of Slo3 potassium channel; then artificially inseminating said animal with said sperm.
Type:
Grant
Filed:
December 18, 2018
Date of Patent:
July 11, 2023
Assignees:
IMV TECHNOLOGIES, UNIVERSITE GRENOBLE ALPES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), SWISSGENETICS
Inventors:
Christophe Arnoult, Eric Schmitt, Guillaume Martinez, Jessica Escoffier
Abstract: The present disclosure provides polypeptides derived from SARS-CoV-2 which have therapeutic use. One such polypeptide is a polypeptide, referred to as “Npep2,” is derived from the SARS-CoV-2 protein N and has at least 50 consecutive amino acids of the amino acid sequence having at least 90% identity with the amino acid sequence that ranges from the residue at position 276 to the residue at position 411 of SEQ ID NO:2. Further described are conjugates wherein a heterologous polypeptide is conjugated or fused to Npep2. The present disclosure further provides vaccines employing the polypeptides, polynucleotides encoding the polypeptides, and methods of vaccinating subjects against SARS-CoV-2 by administering a therapeutically effective amount of one or more of the polypeptides.
Type:
Application
Filed:
May 26, 2021
Publication date:
July 6, 2023
Applicants:
Institut National de la Santé et de la Recherche Médicale (INSERM), Baylor Research Institute, Assistance Publique - Hopitaux de Paris (APHP), Universite Paris Est Creteil Val de Marne
Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.
Type:
Grant
Filed:
February 2, 2018
Date of Patent:
July 4, 2023
Assignees:
Acticor Biotech, Université Paris Cité, Université Paris-XIII, Inserm (Institut National de la Santé et de la Recherche
Médicale), Université Paris-Saclay
Inventors:
Philippe Billiald, Martine Jandrot-Perrus, Gilles Avenard
Abstract: The present invention relates the field of CMV and CMV related diseases. Using a powerful rat model of CMV infection of the embryonic brain, the inventors have looked for the existence of postnatal neurological and neurosensory manifestations, and have tested whether the early pharmacological targeting of microglia during pregnancy impacts on postnatal phenotypes. Particularly, the inventors tested the clodronate and the doxycycline and showed that these compounds improve the postnatal outcome of the baby. Thus, the invention relates to a compound which modifies the microglia for use in the treatment of CMV related diseases in a subject in need thereof.
Type:
Grant
Filed:
October 22, 2018
Date of Patent:
July 4, 2023
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX MARSEILLE
Inventors:
Pierre Szepetowski, Robin Cloarec, Sylvian Bauer, Nadine Bruneau
Abstract: A system and method for analyzing volatile organic compounds (VOCs) adsorbed on an adsorbent membrane, by low-temperature plasma and mass spectrometry (LTP-MS). The system includes a receptacle for receiving the adsorbent membrane, a low-temperature plasma ionizer configured to emit a plasma stream in a plasma emission direction, thereby ionizing the VOCs adsorbed by the membrane and forming a VOC-laden ionized gas, and a mass spectrometer for analyzing the ionized VOCs.
Type:
Application
Filed:
May 20, 2021
Publication date:
June 29, 2023
Applicants:
UNIVERSITE DE LILLE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU)
Inventors:
Isabelle SALZET, Julien FRANCK, Michel SALZET, Flore HERVE
Abstract: New human therapeutic monoclonal antibodies, which are directed against neutrophil proteinase 3. The monoclonal antibodies are specifically directed against a conformational epitope of the neutrophil proteinase 3 and are capable of inhibiting by at least 30% the production for reactive oxygen derivatives by neutrophils. Also, a pharmaceutical composition including as an active substance at least the monoclonal antibody, and a method for early treatment and/or prevention of relapse of granulomatosis with polyangiitis, which includes the administration of the pharmaceutical composition.
Type:
Application
Filed:
October 16, 2020
Publication date:
June 29, 2023
Applicants:
UNIVERSITE DE TOUR, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.
Type:
Application
Filed:
March 6, 2023
Publication date:
June 29, 2023
Applicants:
UNIVERSITE PARIS-SACLAY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT GUSTAVE-ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Abstract: A method is provided for preventing and/or treating heart failure in a subject in need thereof by administering to the subject a therapeutically effective amount of polydextrose. The method may also include the use of polydextrose for preventing cardiac remodeling and/or ventricle dilatation and/or for preventing systolic dysfunction, as well as preventing an increase in bacterial translocation to heart tissue in a subject who suffered from a myocardial infarction.
Type:
Grant
Filed:
January 5, 2021
Date of Patent:
June 27, 2023
Assignees:
VAIOMER, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Inventors:
Christophe Heymes, Rémy Burcelin, Benjamin Lelouvier, Jacques Amar
Abstract: The invention relates to gut microbiota profiles associated with response or resistance to treatments with ICB, in particular with anti-PD1 or anti PD-L1 or anti-PD-L2 antibodies. In particular, the invention pertains to a theranostic method for identifying good responders, to whom an anti-PD1 or anti PD-L1 or anti-PD-L2 can be administered, while a pre-treatment based on FMT and/or immunogenic probiotics is recommended to bad responders exhibiting a dysbiosis. In particular, the present invention pertains to Akkermansia muciniphila as the main commensal species distinguishing responders from progressors and its use alone or with E. hirae for the treatment of antibiotics or gut repertoire insufficiency-associated dysbiosis.
Type:
Grant
Filed:
December 22, 2017
Date of Patent:
June 27, 2023
Assignees:
INSTITUT GUSTAVE ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM, UNIVERSITE PARIS-SACLAY, Insitut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE)
Inventors:
Laurence Zitvogel, Bertrand Routy, Emmanuelle Le Chatelier
Abstract: A computer-implemented method for detecting pathological brain activity patterns from a scalp electroencephalographic signal, the method including the steps of obtaining (A) an electroencephalographic signal as a function of multiple channels and time; identifying (C), for each channel, the zero-crossings of the electroencephalographic signal over a fixed threshold; generating a zero-crossing representation of at least a segment of the obtained electroencephalographic signal with the identified zero-crossings; obtaining (D) a reference family of real functions of time and channels from a zero-crossing statistical analysis of zero-crossing representation of pre-recorded electroencephalographic signals; calculating (E) a matching score by comparing the zero-crossing representation of a segment of the electroencephalographic signal with at least one reference function from the reference family of functions; and computing the matching score as a function of time by sliding the at least one reference function from
Type:
Grant
Filed:
March 30, 2018
Date of Patent:
June 27, 2023
Assignees:
Bioserenity, ICM (Institut Du Cerveau Et De La Moellle Épiniére), APHP (Assistance Publique—Hôpitaux De Paris), Centre National De La Recherche Scientifique, INSERM (Institut National De La Santé Et De La Recherche Médicale), Sorbonne Universite
Inventors:
Jan Pyrzowski, Michel Le Van Quyen, Jean-Eudes Le Douget